Titan Medical (TMDI) Q2 2024 earnings summary

Executive summary

• Reported Q2 2024 results, focusing on cost reductions and progress toward the Conavi Medical merger.

• Amended the amalgamation agreement with Conavi multiple times, extending key deadlines and reducing financing requirements.

Financial highlights

• Cash balance was $3.9 million as of June 30, 2024, down from $7.5 million at year-end 2023.

• Working capital stood at $3.3 million, compared to $5.5 million as of December 31, 2023.

• R&D expenses were nil for Q2 2024, versus $0.4 million in Q2 2023; six-month R&D showed a $0.1 million recovery.

• G&A expenses were $1.1 million for Q2 2024, down from $4.3 million in Q2 2023, reflecting prior cost-cutting.

Significant events and developments

• Amalgamation agreement with Conavi amended three times, extending the outside date to October 10, 2024.

• Minimum concurrent financing requirement reduced from $15 million to $7.5 million.

• Minimum net cash required at closing reduced from US$5 million to US$2 million.